izencitinib

a nonselective inhibitor of JAK1, 2 and 3 and TYK2 with exclusive enteral distribution

Also Known As:

3-((1R,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo(3.2.1)octan-8-yl)propanenitrile; TD-1473; TD1473

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/01/2022 - "Izencitinib (TD-1473), an oral, gut-selective pan-Janus kinase (JAK) inhibitor under investigation for treatment of inflammatory bowel diseases, was designed for optimal efficacy in the gastrointestinal tract while minimizing systemic exposures and JAK-related safety findings. "
2.	Ulcerative Colitis 09/16/2020 - "Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme."
3.	Colitis 09/16/2020 - "Oral TD-1473 administration to mice achieved high, biologically active colonic tissue concentrations with low plasma exposure and decreased oxazolone-induced colitis activity without reducing blood cell counts vs placebo. "